AOD-9604 in Doctor Castillo del Valle — Fat Loss Peptide Research Guide
AOD-9604 research guide for Doctor Castillo del Valle. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers seeking out AOD-9604 in Doctor Castillo del Valle immediately realize that local retail options are essentially nonexistent. What this means for Doctor Castillo del Valle researchers is that your location matters far less than your ability to evaluate vendor quality — and those verification methods are within reach of all serious researchers. What genuinely separates top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Doctor Castillo del Valle researcher needs to evaluate quality systematically.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Doctor Castillo del Valle comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone cannot verify molecular identity. For Doctor Castillo del Valle researchers evaluating new suppliers: a small initial order to verify quality before placing larger orders is what experienced peptide researchers consistently do. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 30 days refrigerated.
Order AOD-9604 — ships to Doctor Castillo del Valle
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Temperature excursions — even short periods above −20°C — can compromise product integrity without detectable changes to appearance; always verify cold chain was maintained during shipping. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers combining AOD-9604 with other compounds should check the research literature for any reported interactions before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
